Nabriva Therapeutics plc

Our lead product, lefamulin, is the first pleuromutilin antibiotic for intravenous and oral administration in humans. We have completed two pivotal Phase 3 trials evaluating the safety and efficacy for the treatment of community-acquired bacterial pneumonia (CABP), the leading cause of infection death and the second most common cause of hospitalization in the United States. Lefamulin met all FDA and EMA primary endpoints in both LEAP 1 and LEAP 2 and was shown to be generally well tolerated. We expect to apply for US marketing approval of lefamulin for the treatment of CABP in the fourth quarter of 2018 and an MAA with the European Medicines Agency a few months later.

 

Bank Name Nabriva Therapeutics plc
Stock Exchange NASDAQ
Symbol NBRV
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region Amarica
Chairman
CEO Dr. Colin Broom
Employees 88
Website www.nabriva.com
Registered Year 2005

 

UpdateContent
UpdateContent
UpdateContent